BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2013 Earnings Results

BioCryst Pharmaceuticals Misses on Revenue, Stock Down 7.56%

BioCryst Pharmaceuticals reported a narrower-than-expected loss per share, but did not disclose revenue figures, which may have disappointed investors. The stock dropped 7.56% in reaction to the lack of revenue information and guidance. Investors are likely concerned about the company's future performance without clear financial targets.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.09	N/A	+16.67%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed a cautious outlook, emphasizing the importance of ongoing research and development. They did not provide specific guidance for future quarters.

Management did not provide specific revenue figures for the quarter.

The company is focused on future product development and market opportunities.

BioCryst Pharmaceuticals Misses on Revenue, Stock Down 7.56%

Key numbers

Management commentary

BioCryst Pharmaceuticals, Inc.

More earnings this week

BioCryst Pharmaceuticals Misses on Revenue, Stock Down 7.56%

Key numbers

Management commentary